Introduction. JW Moul 1,2, RM Mooneyhan 2, T-C Kao 3, DG McLeod 1,2 and DF Cruess 3

Size: px
Start display at page:

Download "Introduction. JW Moul 1,2, RM Mooneyhan 2, T-C Kao 3, DG McLeod 1,2 and DF Cruess 3"

Transcription

1 Prostate Cancer and Prostatic Diseases (1998) 5, 242±249 ß 1998 Stockton Press All rights reserved 1365±7852/98 $ Preoperative and operative factors to predict incontinence, impotence and stricture after radical prostatectomy JW Moul 1,2, RM Mooneyhan 2, T-C Kao 3, DG McLeod 1,2 and DF Cruess 3 1 Urology Service, Department of Surgery & Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC ; 2 Center for Prostate Disease Research, Department of Surgery; and 3 Department of Preventive Medicine and Biometrics, Division of Epidemiology and Biostatistics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD , USA The purpose of this study was to determine the incidence of patient-self reported post prostatectomy incontinence, impotence, bladder neck contracture or stricture, better, same or worse quality of life and willingness for same treatment again in a large group of radical prostatectomy (RP) patients and to determine if these morbidities are predictable with demographic, surgical or prostate cancer (PC) factors. Methods: A patient self-reporting questionnaire was completed and returned by 374 out of 458 eligible (81.7%) RP patients from one center, 267 (72.2%) have been operated since 1990 and all of whom were a minimum six month postoperative (75%>1 y). Questionnaire results were independently analyzed by a third party and correlated to demographic, operative, and tumor factors in an ongoing comprehensive PC database. Results: The patient self-reported incidence of post prostatectomy incontinence (any degree), impotence, and bladder neck contracture or stricture was 72.2, 87.4, and 25.9%, respectively. The reported rate of incontinence requiring protection was 39.0% and only 2.4% had persistent bladder neck contracture/stricture. Pathologic stage (continuous variable) was the only factor to signi cantly predict incontinence and no factor could predict impotence or bladder neck contracture/ stricture in univariate analysis. No factor was predictive of morbidity by multivariate analysis. Despite incontinence and impotence signi cantly affecting QOL self-reporting (P ˆ 0.001, 0.001, respectively) and willingness to undergo RP again (P ˆ 0.001, 0.067, respectively), the majority of patients would choose surgery again. Conclusions: Although radical prostatectomy morbidity is common and affects patient-reported overall QOL, most patients would choose the same treatment again. Demographic, preoperative, operative, and tumor factors did not reliably predict patient-reported morbidity in this series. Keywords: prostate; cancer; incontinence; impotence; stricture; radical prostatectomy Introduction Because of the aging population, PSA-screening, and public awareness of prostate cancer (PC), the use of radical prostatectomy (RP) has increased dramatically Correspondence: Dr JW Moul, Department of Surgery, USUHS, 4301 Jones Bridge Road, Bethesda, MD 20814±4799, USA. Received 3 December 1997; revised 24 February 1998; accepted 25 February 1998 over the last decade. 1 This increase has led to the recognition and reality of postoperative morbidities including impotence, 2 incontinence, 3 and bladder neck contracture and/or urethral stricture and their potential impact on quality of life. 4 A number of recent patient surveys have documented the incidence of these problems in the Medicare, 5 CHAMPUS, 6 managed care, 7 private sectors, 8 and by multicenter pre- and post questionnaire. 9 None of the studies to date have attempted to de ne patient, surgical and/or tumor factors that may be risk factors for the

2 subsequent occurrence of these patient-reported outcomes. The goal of this study was to conduct a large patient self-reported questionnaire survey of sexual, urinary, and quality of life and to correlate results to an ongoing retrospective and prospective PC database to examine for factors that may predict the likelihood of these morbidities. Materials and methods A questionnaire was designed to assess the presence and degree of patient self-reported post-prostatectomy incontinence (PPI), impotence (IMP), bladder neck contracture and/or urethral stricture (S), quality of life (QOL) and willingness to undergo the same cancer treatment again, this was based on the instrument of Fowler et al 5 and is available upon request, and is also given in Table 2. The questionnaire was eld-tested for comprehension and clarity by 50 members of the Walter Reed US TOO, Inc., prostate cancer support group prior to study use. Study subjects were patients who had been related by radical retropubic prostatectomy at Walter Reed Army Medical Center between 1973±1994. Of the 471 patients treated by RP during this interval, 13 had died at the survey time of March 1995 leaving 458 patients to whom the survey was mailed. A business reply envelope was included with the questionnaire and after 30 d a followup letter was mailed to remind nonresponders. After 60 d, 374 surveys had been returned (81.7%) which formed the study cohort, for these responders, 96 (25.7%) completed the survey between six months and one year from surgery, 134 (35.8%) between 1±3 y, and 144 (38.5%) greater than 3 y from RP. As part of the Department of Defense Center for Prostate Disease Research (CPDR) program, Walter Reed Army Medical Center is one of ten military hospitals designated to collect prospective and retrospective comprehensive clinical data on all prostate cancer patients. As of 1 January 1994, data collection was prospective on all new PC patients at Walter Reed and similar retrospective data has also been collected on all patients treated since 1970 through inpatient and outpatient record review and interviews of living patients. Standardized data collection forms for transrectal ultrasound biopsy, registration, staging, surgery, radiation, hormonal, cryotherapy, brachytherapy, follow-up, and necropsy have been developed and are available upon request. Data has been collected by physicians and research personnel. This data is entered and maintained on a relational database (Oracle Corporation). The questionnaire project and CPDR database have been approved by the Walter Reed Department of Clinical Investigation Human Use Institutional Review Board. Grading conformed to the Gleason system and pathologic staging to the 1992 TNM system. 10; 11 The de nition of incontinence from the patient questionnaire and used for subsequent analysis in Tables 3 and 4 was for any dripping or leaking problems after surgery and the use of protection (pads, diapers, rubber pants or clamps). Impotence was de ned as any patient who could have erections when stimulated before surgery but could not have full erections after surgery. Statistical analysis Questionnaire data on the 374 patients and the corresponding complete diagnostic, demographic, staging and surgical data for these patients were provided to two of us (TK, DFC) for independent tabulation and statistical analysis, a 5% signi cance level was utilized in all statistical tests. The Statistical Analysis System (SAS) statistical computer software package was used to do all statistical calculations. Chi-square tests were used to determine if there is a signi cant association between categorical risk factors and categorical outcome variables [for example, race (black/white) vs impotence (yes/no)]. Analysis of variance (ANOVA) or two-sample t-test was used to test for statistical signi cance of the difference in the means of continuous risk factors variables across the categories of outcome variables (for example, average tumor volume in those incontinent compared to average tumor volume in those not incontinent post-surgery). The multivariate approach of stepwise logistic regression was used to determine the effect of a number of risk factors simultaneously on the dichotomous outcome variables of incontinence (absence vs presence) and quality of life (better or same vs worse). The risk factors considered in the construction of the logistic regression models included age at surgery, race, surgical era, Gleason sum, pathologic T stage, PSA, operation time, and estimated blood loss (EBL). Stepwise logistic regression rst identi es the risk factor that is the strongest predictor of the outcome variable of interest, followed by the next strongest, etc., until there is no statistically signi cant bene t in adding new risk factors to the prediction model. Additionally, at each step, any risk factor already present in the model is examined to see if it still is a statistically important predictor of the outcome variable when other risk factors have been added to the model. To determine the placement and retention of risk factors in the model, signi cance levels for entry of 15% and removal of 20% were used; these more liberal levels are common in stepwise logistic regression model building. Results The demographic, stage, grade and surgical data contained in the CPDR database of the 374 patient who responded to the patient-self-reported questionnaire is given in Table 1 and the data from the questionnaire is given in Table 2. Notably, the vast majority (86.1%) of patients were less than or equal to 70 y of age at the time of RP and the mean age was 63.2 y. There was racial diversity with 21.9% African American patients and the majority (63.6%) of all patients were married. Gleason sum grade was similar to other series with a majority of patients (61.3%) being intermediate (Gleason 5±7) grade. Similarly, pathologic stage was similar to other reports with 162 (43.3%) organ-con ned and 199 (53.2%) nonorgan-con ned patients. Mean pre-treatment PSA for 308 evaluable patients (66 patients treated prior to PSA availability) was 9.80 ng/ml with a median of 6.75 ng/ml and range of 0.1±112.5 ng/ml. A majority (267±71.2%) of patients were treated since 1990 and the operative time (4.15 hours-mean) and operative estimated blood loss 243

3 244 (2069 cc mean, 1700 cc median) were similar to other reports during this era from teaching hospitals. Most noteworthy regarding the survey results in Table 2 are the rates of post prostatectomy incontinence and impotence. Fully, 270 patients (72.2%) reported some degree of incontinence at the time of survey, however, 204 (54.6%) reported a few drops or less than a tablespoon and 96 (25.6%) noted leakage once or less a day. Furthermore, among the 374 respondents, protection by using pads (32.6%), diapers (9.6%) or clamps (2.7%) was reported. Of 320 preoperative potent patients, 41 patients (12.8%) reported natural full erections postoperatively and a signi cant additional number were using penile self-injection (40 patients 10.7%), vacuum devices (125 patients 33.4%) or had a penile prosthesis (50 patients 13.4%). Although 97 patients (25.9%) reported at least one episode of bladder neck contracture or stricture requiring treatment, only 9 (2.4%) patients reported that the problem was not resolved at the time of the survey. Regarding overall patient-perceived quality of life, 214 Table 1 Demographic, stage, grade and surgical data of 374 racial prostatectomy patients (3.93) (1700) (3.61) Age at surgery: Mean SE (median) a (63.8) 70 y 322 (86.1%) >70 y 46 (12.3%) Unknown 6 (1.6%) Race Caucasian 285 (76.2%) Black 82 (21.9%) Other 7 (1.9%) Marital status Married 238 (63.6%) Single/divorce/widowed 134 (35.8%) Unknown 2 (0.5%) Gleason sum grade (RP specimen min) 4 45 (12.0%) 5 75 (20.0%) 6 77 (20.5%) 7 78 (20.8%) 8 34 (9.1%) Unknown/not performed 65 (17.4%) Pathologic stage T2a 48 (12.8%) T2b 24 (6.4%) T2c 90 (24.1%) T3a 101 (27.0%) T3b 58 (15.5%) T3c 40 (10.7%) Unknown 13 (3.5%) Pre-treatment PSA mean (median) b (6.75) Surgical era < (27.5%) (71.1%) unknown 5 (1.3%) Operation time (h) mean SE (median) c Estimated blood loss (cc) mean SE (median) d Total tumor volume (cc) mean SE (median) e a Based on 368 patients. b PSA ˆ maximum of pre-biopsy and pre-treatment value, ng/ml, based on 308 patients (82.4% of cohort). c Based on 310 patients. d Based on 315 patients. e Based on 96 patients. (57.2%) patients reported it to be the same or better and 281 (75.1%) patients would choose the same treatment again. Table 3a provides the bivariate analysis of demographic, tumor and surgical variables with incontinence (any self-reported incontinence and using protectionpads, diapers, clamps from Table 2, II2 and 3), impotence (no full erections after RP but having full erection before from Table 2, III2) and stricture (self-reported bladder neck contracture or stricture requiring treatment from Table 2, IV1). In the bivariate analysis, there was no demographic, preoperative or operative variable that was signi cantly associated with these three patient self-reported morbidities. Potent patients (mean 60.4 y) were younger than impotent patients (63.1 y) which tended to signi cance (P ˆ 0.083). Similar non-signi cant trends were seen for incontinence and Gleason sum>6 (P ˆ 0.074), and bladder neck contracture/stricture and higher estimated blood loss (P ˆ 0.089). Without dichotomizing pathologic stage (that is, using all categories from Table 1), we found that incontinence was signi cantly associated with higher pathologic stage (P ˆ 0.007) and a trend for higher Gleason sum grade (P ˆ 0.073). Similarly, with continuous Gleason sum grade, impotence was slightly associated with advancing grade (P ˆ 0.067). Higher tumor volume (available for 94 patients) as a continuous variable was marginally associated with impotence (P ˆ 0.083). For patient self-reported quality of life and choosing the same treatment again, Table 3b reveals three signi cant associations. Patients reporting worse quality of life were younger (P ˆ 0.023), blacks reported better QOL (P ˆ 0.006), and patients treated prior to 1990 reported a better QOL (P ˆ 0.017). None of the other bivariate preoperative or operative factors were related to QOL or reported willingness to undergo surgery again. Higher Gleason sum grade as a continuous variable was associated with not choosing RP again (P ˆ 0.004). Table 4 provides data on the correlation of patient selfreported quality of life and willingness to undergo radical prostatectomy again with self reported incontinence, impotence and bladder neck contracture/stricture. For patients who reported incontinence, 57.2% reported a worse QOL than before treatment compared to 29.0% of the continent men (P<0.001). Similarly, 47.2% of impotent patients reported worse QOL compared to 18.4% who regained potency (P ˆ 0.001). There was no correlation of self reported bladder neck contracture/stricture and QOL. Regarding self-reported willingness to undergo surgery again, 28.1% of incontinent men would not choose surgery again vs 13.3% of those who reported continence (P ˆ 0.001). Less signi cant trends to not choosing RP again were seen for impotence and bladder neck contracture/stricture. Overall, 71.9±79.2% of incontinent or impotent men or those with bladder neck contracture/stricture report that they would choose the same treatment again and 42.8±56.4% had the same or better self-reported QOL despite reporting these morbidities. Multivariate stepwise logistic regression analyses were performed for a number of outcome variables. For the outcome variable incontinence (absence vs presence), stepwise logistic regression selected only one surgical variable, estimated blood loss (odds ratio (OR) ˆ ,

4 Table 2 Patient self-reported questionnaire results in 374 radical prostatectomy patients 245 Yes (%) No (%) Unknown/not applicable not answered (%) I. Cancer recurrence questions 1. As far as you know, do you have prostate cancer anywhere now? 43 (11.5) 319 (85.3) 12 (3.2) 2. Since your prostate surgery, have you had: a. Any pills or injections of estrogens or hormones for PC? 26 (7.0) 342 (91.4) 6 (1.6) b. Surgery to remove testicles? 18 (4.8) 336 (89.8) 20 (5.3) c. Radiation treatments? 74 (19.8) 286 (76.5) 14 (3.7) II. Incontinence questions 1. After prostate surgery some men nd that they have a problem with dripping or leaking urine. a. Did you have that problem to any degree immediately after your 300 (80.2) 69 (18.4) 5 (1.3) prostate surgery? b. Did you have any additional surgery to help stop dripping or 39 (10.4) 327 (87.4) 8 (2.1) leaking? 2. a. Do you currently have any problem at all with dripping or leaking? 270 (72.2) 101 (27.0) 3 (0.8) b. If yes, have you experienced any of the following in the past month? dripped or leaked urine when you coughed or sneezed? 186 (49.7) 75 (20.1) 113 (30.2) c. Dripped or leaked urine when bladder was full before getting to 192 (51.3) 70 (18.7) 112 (29.9) bathroom? d. When you drip about how much usually comes out? a few drops 126 (33.7) less than a tablespoon 78 (20.9) a tablespoon or more 52 (13.9) unknown/not answered 118 (31.6) e. How often do you drip or leak urine? less than once a day 48 (12.8) once a day 48 (12.8) more than once a day 150 (40.1) 3. Do you use any of the following to help with wetness at this time? pads 122 (32.6) 148 (71.7) 104 (27.8) adult diapers 36 (9.6) 234 (62.6) 104 (27.8) rubber pants 2 (0.5) 268 (71.7) 104 (27.8) clamps 10 (2.7) 260 (69.5) 104 (27.8) 4. Have you tried any of the following for leakage? biofeedback 3 (10.8) 267 (71.4) 104 (27.8) behavioral training 30 (8.0) 240 (64.2) 104 (27.8) pelvic exercise training 141 (37.7) 128 (34.2) 105 (28.1) III. Sexual function questions 1. The year prior to your prostate surgery, could you have erections 320 (85.6) 52 (13.9) 2 (0.5) when you were stimulated? 2. Since your prostate surgery, are you capable of having full erections? 41 (11.0) 327 (87.4) 6 (1.6) 3. Since your prostate surgery, have you tried any of the following? penile injections (shots) 40 (10.7) 286 (76.5) 48 (12.8) vacuum suction device 125 (33.4) 230 (61.5) 19 (5.1) penile implant surgery 50 (13.4) 305 (81.6) 19 (5.1) 4. Are you happy with your degree of sexual function in general? very satis ed 41 (11.0) somewhat satis ed 63 (16.8) somewhat unsatis ed 87 (23.3) very unsatis ed 132 (35.3) IV. Post surgical stricture questions 1. One problem some patients have after prostate surgery is called strictures. Strictures are scar tissue that can form in the urinary tract that can make it dif cult to urinate. a. Since your prostate surgery, has a doctor had to dilate your urinary 97 (25.9) 266 (71.1) 11 (2.9) tract or perform any surgery to treat strictures? b. Is this stricture problem now resolved? 81 (21.7) 9 (2.4) 284 (75.9) V. Comments 1. After your prostate cancer treatment, do you feel your overall quality of life is: better than before 63 (16.8) same as before 151 (40.4) worse than before 142 (38.0) unknown/not answered 18 (4.8) 2. If you had the choice of cancer treatment today, would you take the same course of treatment? 281 (75.1) 66 (17.6) 27 (7.2)

5 246 Table 3a Bivariate analysis of demographic, tumor and surgical variables related to outcome variables: incontinence, impotence and stricture Incontinence Impotence Surgical stricture? Yes No Yes No Yes No Total 147 (40%) 224 (60%) 277 (88%) 38 (12%) 97 (27%) 266 (73%) Age at surgery.(y) Mean.(SE) 63.1.(0.5) 63.2.(0.5) 63.1.(0.4) 60.4.(1.4) 62.7.(0.6) 63.4.(0.4) N Race Black 32.(40%) 49.(60%) 62.(87%) 9.(13%) 16.(20%) 64.(80%) White 113.(40%) 170.(60%) 212.(89%) 26.(11%) 81.(29%) 195.(71%) Surgical era year (38%) 64.(62%) 74.(85%) 13.(15%) 31.(32%) 67.(68%) year (41%) 156.(59%) 201.(89%) 24.(11%) 65.(25%) 195.(75%) PSA.(maximum level of prebiopsy and pre-treatment PSAs) Mean.(SE) 10.0.(1.2) 9.7.(0.9) 10.3.(0.8) 8.1.(1.5) 11.3.(1.5) 9.3.(0.8) N Gleason sum 6 72.(37%) 123.(63%) 148.(87%) 23.(13%) 45.(23%) 148.(77%) 6 53.(47%) 59.(53%) 85.(91%) 8.(9%) 27.(25%) 81.(75%) Pathologic T stage T2a,b,c 59.(36%) 104.(64%) 128.(89%) 16.(11%) 45.(28%) 114.(72%) T3a,b,c 86.(42%) 118.(58%) 146.(87%) 22.(13%) 51.(26%) 149.(74%) Operation time.(h) Mean.(SE) 4.2.(0.1) 4.1.(0.1) 4.1.(0.1) 4.2.(0.2) 4.3.(0.1) 4.1.(0.1) N Estimated blood loss.(cc) Mean.(SE) 2238.(184) 1939.(99) 2035.(116) 2063.(298) 2448.(291) 1930.(79) N Tumor total volume.(cc) Mean.(SE) 5.25.(0.7) 6.3.(1.0) 6.1.(0.7) 3.8.(1.1) 5.6.(1.1) 6.0.(0.8) N Chi-square or two-sample t-test was used to decide if a risk factor was related to each outcome variable. No signi cance was found (P>5%). Table 3b Bivariate analysis of demographic, tumor and surgical variables related to outcome variables: quality of life, treatment again Quality of life Treatment again Better Same Worse Yes No Total 63 (18%) 151 (42%) 142 (40%) 281 (81%) 66 (19%) Age at surgery.(y) Mean.(SE) 64.8.(0.8) 63.6.(0.6) 62.1.(0.6) a 63.0.(0.4) 63.4.(0.9) N Race Black 22.(28%) 24.(31%) 32.(41%) a 58.(76%) 18.(24%) White 38.(14%) 124.(46%) 109.(40%) 216.(82%) 48.(18%) Surgical era year (22%) 49.(50%) 27.(28%) a 79.(85%) 14.(15%) year (16%) 100.(39%) 113.(45%) 198.(79%) 52.(21%) PSA. (maximum level of prebiopsy and pre-treatment PSAs) Mean.(SE) 9.4.(1.2) 8.6.(0.7) 11.2.(1.5) 9.6.(0.8) 11.4.(1.9) N Gleason sum 6 34.(18%) 78.(41%) 77.(41%) 151.(80%) 37.(20%) 6 17.(16%) 45.(42%) 45.(42%) 83.(82%) 18.(18%) Pathologic T stage T2a,b,c 23.(15%) 75.(47%) 61.(38%) 130.(84%) 24.(16%) T3a,b,c 39.(20%) 76.(39%) 79.(41%) 150.(79%) 39.(21%) Operation time.(h) Mean.(SE) 4.2.(0.1) 4.2.(0.1) 4.1.(0.1) 4.1.(0.1) 4.2.(0.2) N Estimated blood loss.(cc) Mean.(SE) 2290.(253) 2071.(172) 1930.(119) 2010.(85) 2266.(372) N Tumor total volume.(cc) Mean.(SE) 5.47.(1.1) 5.2.(1.0) 6.5.(1.2) 6.0.(0.7) 5.5.(1.4) N a Denotes signi cant.(p<5%), where Chi-square or two-sample t-test was used to decide if a risk factor was related to each outcome variable.

6 Table 4 Comparison of patient self-reported incontinence, impotence, and stricture and self-reported quality of life and willingness to undergo radical prostatectomy again 247 Quality of life Treatment again Better Same Worse P-value b Yes No P-value Incontinence Yes 16 (11.6) 43 (31.2) 79 (57.2) a 97 (71.9) 38 (28.1) a No 46 (21.2) 108 (49.8) 63 (29.0) 183 (86.7) 28 (13.3) Impotence Yes 35 (13.2) 105 (39.6) 125 (47.2) 206 (79.2) 54 (20.8) No 11 (29.0) 20 (52.6) 7 (18.4) a 34 (91.9) 3 (8.1) Stricture Yes 15 (16.0) 38 (40.4) 41 (43.6) (73.9) 24 (26.1) a No 47 (18.3) 110 (43.0) 99 (38.7) 209 (83.6) 41 (16.4) a Indicates signi cant association between the two corresponding variables. b P-value of Mantel-Haenszel Chi-square test adjusted or the surgical era (before or after 1990). its 95% con dence interval (CI) ˆ [0.9996, ], P ˆ , N ˆ 230) in the nal model. This implied that a cubic centerimeter incremental increase in blood loss would slightly decrease the odds of having continence. For another outcome variable, quality of life (dichotomized as `better or same' vs `worse'), the nal logistic model selected age (OR ˆ 1.047, 95% CI ˆ [1.004, 1.092], P ˆ 0.309), surgical era (year >1990 vs <1990: OR ˆ 0.458, 95% CI ˆ [0.183, 1.147], P ˆ ) and PSA (OR ˆ 0.981, 95% CI ˆ [0.958, 1.005], P ˆ ; N ˆ 221). By using the same set of potential risk factors, without dichotomizing pathologic stage and Gleason sum grade, similar results were found except for quality of life in which this nal logistic model selected age (OR ˆ 1.050, 95% CI ˆ [1.006, 1.095], P ˆ , and PSA (OR ˆ 0.977, 95% CI ˆ [0.951, 1.004], P ˆ ; N ˆ 216). Discussion This is the rst patient-self-reported outcome survey study that has been correlated to a database of patient, tumor and surgical variables in an attempt to discover potential predictors of common radical prostatectomy morbidities of impotence, incontinence and urethral/ bladder neck contracture/strictures. To our surprise, few factors were correlated to these three morbidity outcomes. Pathologic stage (continuous variable) was the only statistically signi cant factor associated with post prostatectomy incontinence. High Gleason sum (>6) was marginally (P ˆ 0.07) associated with incontinence as well. Not surprisingly, younger men were more likely to regain potency (P ˆ 0.083). Furthermore, higher Gleason sum (P ˆ 0.067) and tumor volume (P ˆ 0.083) as continuous variables were marginally associated with impotence. A higher estimated blood loss was the only marginal (P ˆ 0.09) risk actor for bladder neck contracture/stricture. In multiple logistic regression analysis using both binary data and continuous data for stage and grade, no factor remained signi cant to predict incontinence and only estimated blood loss trended to signi cance (P ˆ 0.065). With a larger study, it is possible that one or more of these factors may emerge that convincingly predict these three common morbidities. Alternatively, these morbidities may be truly based on individual patient or surgical factors. Self-reported worse quality of life was associated with incontinence and impotence, however, the majority of men reported that they would choose radical prostatectomy again. Despite our careful attempt to link patient self-reported outcome to database variables, there are a number of limitations to our study. Our quality of life assessment was a crude, simple question about QOL and was not based on a validated QOL questionnaire. Our question about choosing the same treatment again is dubious since most studies that ask this question whether it be radiation or surgical procedures report positive replies by patients. We were unable to assess the impact of type of nerve sparing surgery or impact of primary surgeon, we were not con dent in reliably assigning nerve sparing status from operation reports from the retrospective database patients prior to This is unfortunate since two recent reports came to different conclusions regarding nervesparing and continence. 9,12 Finally, even though we asked about pretreatment potency we did not control for preoperative continence. Fortunately, a recent survey found that pretreatment incontinence was reported by less than 5% of similar patients. 9 Despite these limitations, we believe our study adds to the growing body of literature in this area. Our self-reporting survey results are similar to recent reports even though our patients were somewhat younger (mean±63.2 y) on average than a recent similar survey of Medicare bene ciaries. 5 Fowler et al 5 found a 40% incidence of incontinence (any degree), a 20% incidence of stricture requiring treatment, and a 11% potency rate in 757 Medicare patients who underwent RP. In a smaller survey of similarly aged men (mean 65 y) from one private practice, Lim et al 8 noted a 43% incontinence rate (any degree) and only 4% of patients had spontaneous erections suf cient for vaginal penetration. Jonler et al 13 noted a 74% rate of incontinence after RP with 34% noting that dripping was a signi cant problem. Lim et al 8 found that 82 out of 89 (92%) surveyed patients would choose RP again, in line with our rate of 81.1%. Most recently, Talcott et al 9 conducted a preoperative and postoperative prospective survey of RP patients from multiple hospitals. Even with bilateral nerve sparing RP, only 11% of their cohort were fully potent. Unilateral nerve sparing was not signi cantly better than non-nerve-sparing for preserving potency in their study. Interestingly, regarding

7 248 post prostatectomy incontinence, 14% of Talcott et al 9 nonnerve sparing patients were wearing pads but 50% of nerve sparing patients required pads. In contrast, Eastham et al 12 found that nerve-sparing RP was an independent predictor of improved continence. Our quality of life assessment was a simple question regarding the patients self reported perceived QOL in relation to before treatment. We did not employ a standardized QOL instrument as other investigators 7,8 and this was a limitation, however, this was not the primary focus of our study. Despite this, our simple QOL assessment did correlate to morbidity. Similar to Lim et al 8 and Litwin et al 7 we found that incontinence and impotence did impact patient self-reported QOL. Overall, approximately 40% of this cohort of 374 RP patients reported a worse QOL than prior to treatment and it was highly related to incontinence and impotence. Post-prostatectomy incontinence is a common problem in the era of increased use of radical prostatectomy as treatment for prostate cancer. 14,15 Although initially felt to be related to bladder and sphincteric dysfunction with similar frequency, recent study suggests that sphincteric etiology predominates. 16 With this in mind, it may be surprising to some that operation time, blood loss, pretreatment PSA and tumor volume did not predict incontinence. Either these factors do not uniformly in uence risk of incontinence or our study was too small to detect a signi cant difference. Regarding age, Catalona and Bigg 20 also did not nd an association that older men were more likely to experience post prostatectomy incontinence. However, our study as well as that of Catalona and Bigg is skewed toward younger carefully-selected otherwise healthy men. It is possible that a study with a higher proportion of older men with comorbidities or more advanced disease may show that age is associated with incontinence. Similarly, had we had more men with locally advanced (stage C or T3B,C) disease there may have been an independent association of post prostatectomy incontinence and stage. Tumor volume assessed by whole-mount three dimension reconstruction was only available for 94 patients; this factor may have predicted morbidity in a larger cohort. It was reassuring that despite more locally advanced disease, 17 black men treated by RP did not have a higher risk of these three morbidities. Furthermore, the percentage of black and white men reporting worse quality of life was similar (40 vs 41%) and blacks were actually more likely to report better post-operative QOL than whites (28 vs 14%). The rate of return of potency in the era of nerve sparing RP is a debated issue. Although potency rates in reports from centers of excellence have ranged form 54±71%, 18±20 these are selected populations and the potency is based on clinic visits. The patient self reported survey results from less selected groups by us and others 5,8,9 is probably more re ective of the scope of morbidity in general community practice. Only younger age and low Gleason ( 4) were found to predict return of potency. Our results are very similar to the recent report of Talcott et al 9 in which 11% of bilateral nerve sparing patients who had pre-operative potency were fully potent at one year post-operatively. Furthermore, 100% of unilateral nerve sparing and non-nerve sparing patients reported inadequate erections. Although this current study focused on one treatment, radical prostatectomy, there is an urgent need to conduct similar studies of the variety of treatments now used for localized prostate cancer including external beam radiation, brachytherapy and cryotherapy. European investigators have embarked on such studies, 21 however, much more work is needed. Conclusions In a patient self-reported questionnaire and database study of 374 radical prostatectomy patients of multiple surgeons from one centre predominantly treated in the late 1980s and early 1990s, impotence and incontinence were higher than generally recognized. Any degree of incontinence was reported by 72.2%, 39.0% were wearing protection, but the majority had mild stress incontinence. Impotence was reported by 87.2% of the 320 men who were potent preoperatively. Despite these side effects, a majority of men report the same or better quality of life after operation and the majority would choose the same treatment again. Similar studies of mid-to-late 1990s era patients should be conducted to determine if improvements in surgical technique result in higher patient satisfaction. Acknowledgements This research was supported by the following grants: Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC, Grant No and The Center for Prostate Disease Research, a program of Henry M. Jackson Foundation for the Advancement of Military Medicine, 1401 Rockville Pike, Suite 600, Rockville, MD , Grant No References 1 Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation and outcomes. JAMA 1993; 265: 2633± Ofman US. Sexual quality of life in men with prostate cancer. Cancer 1995; 75: 1949± Blaivas JG. Urinary incontinence after radical prostatectomy. Cancer 1995; 75: 1978± Litwin MS. Health-related quality of life after treatment for localized prostate cancer. Cancer 1995; 75: 2000± Fowler FJ et al. Patient-reported complications and follow-up treatment after radical prostatectomy. Urology 1993; 42: 622± Optenberg SA, Wojcik BE, Thompson IM. Morbidity and mortality following radical prostatectomy: A national analysis of civilian health and medical program of the Uniformed Services (CHAMPUS) bene ciaries. J Urol 1995; 153: 1870± Litwin MS et al. Quality of life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129± Lim AJ et al. Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol 1995; 154: 1420± Talcott JA et al. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Nat Cancer Inst 1997; 89: 1117±1123.

8 10 Gleason DF and the Veterans Administration Cooperative Urological Research Group. Histological grading and clinical staging of prostate carcinoma. In: Tannenbaum M (ed). Urologic Pathology: The Prostate. Lea and Febiger: Philadelphia, 1977, pp 171± Ohori M, Wheeler TM, Scardino PT. The new American joint committee on cancer and international union against cancer TNM classi cation of prostate cancer. Cancer 1994; 73: 104± Eastham JA et al. Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996; 156: 1707± Jonler M, Messing EM, Rhodes PR, Bruskewitz RC. Sequelae of radical prostatectomy. Br J Urol 1994; 74: Moul JW. An important goal of prostatectomy: minimizing incontinence. Contemp Urol 1994; 6: 15± Moul JW. For incontinence after prostatectomy, tap a diversity of treatments. Contemp Urol 1994; 6: 78± Chao R, Mayo ME. Incontinence after radical prostatectomy: detrusor or sphincter causes. J Urol 1995; 154: 16± Moul JW et al. Prostate-speci c antigen values at the time of prostate cancer diagnosis are higher in African-American men. J Am Med Assoc 1995; 274: 1277± Walsh PC, Epstein JI, Lowe FC. Potency following radical prostatectomy with wide unilateral excision of the neurovascular bundle. J Urol 1987; 138: Leandri P, Rossignol G, Gautier JR, Ramon J. Radical retropubic prostatectomy: morbidity of quality of life. Experience with 620 consecutive cases. J Urol 1992; 147: Catalona WJ, Bigg SW. Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 1990; 143: Fossa SD et al. In uence of urological morbidity on quality of life in patients with prostate cancer. Eur Urol 1997; 31 (Suppl 3): 3±8. 249

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon

More information

Patient-reported Sexual Function After Nerve-sparing Radical Retropubic Prostatectomy

Patient-reported Sexual Function After Nerve-sparing Radical Retropubic Prostatectomy European Urology European Urology 42 (2002) 118±124 Patient-reported Sexual Function After Nerve-sparing Radical Retropubic Prostatectomy Joachim Noldus *, Uwe Michl, Markus Graefen, Alexander Haese, Peter

More information

Department of Urology, Cochin hospital Paris Descartes University

Department of Urology, Cochin hospital Paris Descartes University Technical advances in the treatment of localized prostate cancer Pr Michaël Peyromaure Department of Urology, Cochin hospital Paris Descartes University Introduction Curative treatments of localized prostate

More information

Combined Reporting of Cancer Control and Functional Results of Radical Prostatectomy $

Combined Reporting of Cancer Control and Functional Results of Radical Prostatectomy $ European Urology European Urology 44 (2003) 656 660 Combined Reporting of Cancer Control and Functional Results of Radical Prostatectomy $ Laurent Salomon a,*, Fabien Saint a, Aristotelis G. Anastasiadis

More information

POTENCY, CONTINENCE AND COMPLICATIONS IN 3,477 CONSECUTIVE RADICAL RETROPUBIC PROSTATECTOMIES

POTENCY, CONTINENCE AND COMPLICATIONS IN 3,477 CONSECUTIVE RADICAL RETROPUBIC PROSTATECTOMIES 0022-5347/04/1726-2227/0 Vol. 172, 2227 2231, December 2004 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000145222.94455.73 POTENCY, CONTINENCE

More information

Erectile Function Before and After Non-Nerve-Sparing Retropubic Radical Prostatectomy

Erectile Function Before and After Non-Nerve-Sparing Retropubic Radical Prostatectomy Archives of Urology ISSN: 2638-5228 Volume 1, Issue 2, 2018, PP: 5-9 Erectile Function Before and After Non-Nerve-Sparing Retropubic Radical Prostatectomy Jørgen Bjerggaard Jensen, MD 1, Jørgen K. Johansen,

More information

Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy

Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical

More information

NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.

NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1. NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low

More information

Patient-Reported Impotence and Incontinence After Nerve-Sparing Radical Prostatectomy

Patient-Reported Impotence and Incontinence After Nerve-Sparing Radical Prostatectomy Patient-Reported Impotence and Incontinence After Nerve-Sparing Radical Prostatectomy James A. Talcott, Patricia Rieker, Kathleen J. Propert, Jack A. Clark, Kenneth I. Wishnow, Kevin R. Loughlin, Jerome

More information

Potency after unilateral nerve sparing surgery: a report on functional and oncological results of unilateral nerve sparing surgery

Potency after unilateral nerve sparing surgery: a report on functional and oncological results of unilateral nerve sparing surgery Potency after unilateral nerve sparing surgery: a report on functional and oncological results of unilateral nerve sparing surgery F Van der Aa 1, S Joniau 1, D De Ridder 1 & H Van Poppel 1 * 1 Department

More information

da Vinci Prostatectomy

da Vinci Prostatectomy da Vinci Prostatectomy Justin T. Lee MD Director of Robotic Surgery Urology Associates of North Texas (UANT) USMD Prostate Cancer Center (www.usmdpcc.com) Prostate Cancer Facts Prostate cancer Leading

More information

CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM

CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN

More information

Prostate Cancer Dashboard

Prostate Cancer Dashboard Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment

More information

PATIENT-REPORTED COMPLICATIONS AFTER CRYOABLATION THERAPY FOR PROSTATE CANCER

PATIENT-REPORTED COMPLICATIONS AFTER CRYOABLATION THERAPY FOR PROSTATE CANCER ADULT UROLOGY PATIENT-REPORTED COMPLICATIONS AFTER CRYOABLATION THERAPY FOR PROSTATE CANCER ROBERT A. BADALAMENT, DUKE K. BAHN, HAROLD KIM, ANIL KUMAR, JEANETTE M. BAHN, AND FRED LEE ABSTRACT Objectives.

More information

Policy #: 370 Latest Review Date: December 2013

Policy #: 370 Latest Review Date: December 2013 Name of Policy: Nerve Graft in Association with Radical Prostatectomy Policy #: 370 Latest Review Date: December 2013 Category: Surgery Policy Grade: B Background/Definitions: As a general rule, benefits

More information

Inception Cohort. Center for Evidence-Based Medicine, Oxford VIP-- Inception Cohort (2008) Nov Dec

Inception Cohort. Center for Evidence-Based Medicine, Oxford VIP-- Inception Cohort (2008) Nov Dec VIP-- Inception Cohort (28) Robotic Prostatectomy: Oncological and Functional Outcomes after 4 cases The Donald Smith Lecture Nov 2- Dec 28---- ----42 patients Patient 1 to patient 38 PSA follow-up -------3481

More information

ABOUT MEN WILL BE

ABOUT MEN WILL BE ORIGINAL CONTRIBUTION Comparison of ations by Urologists and Oncologists for Treatment of Clinically Localized Prostate Cancer Floyd J. Fowler, Jr, PhD Mary McNaughton Collins, MD, MPH Peter C. Albertsen,

More information

Urethral catheter removal 3 days after radical retropubic prostatectomy is feasible and desirable

Urethral catheter removal 3 days after radical retropubic prostatectomy is feasible and desirable Urethral catheter 3 days after radical retropubic prostatectomy is feasible and desirable (2002) 5, 291 295 ß 2002 Nature Publishing Group All rights reserved 1365 7852/02 $25.00 www.nature.com/pcan JM

More information

Prostate Cancer Case Study 1. Medical Student Case-Based Learning

Prostate Cancer Case Study 1. Medical Student Case-Based Learning Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You

More information

Intussusception of the bladder neck does not promote early restoration to urinary continence after non-nervesparing radical retropubi c prostatectomy

Intussusception of the bladder neck does not promote early restoration to urinary continence after non-nervesparing radical retropubi c prostatectomy Blackwell Science, LtdOxford, UKIJUInternational Journal of Urology0919-81722004 Blackwell Publishing Asia Pty LtdMarch 2004123275279Original ArticleIntussusception of the bladder neck and early continencei

More information

Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors

Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors 2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.

More information

TECHNIQUE UPDATE RIU MedReviews, LLC

TECHNIQUE UPDATE RIU MedReviews, LLC RIU 0041 TECHNIQUE UPDATE Sural Nerve Interposition Grafting During Radical Prostatectomy Kevin M. Slawin, MD,* Eduardo I. Canto, MD,* Shahrokh F. Shariat, MD,* John L. Gore, MD,* Edward Kim, MD, Michael

More information

2017 American Medical Association. All rights reserved.

2017 American Medical Association. All rights reserved. Supplementary Online Content Borocas DA, Alvarez J, Resnick MJ, et al. Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3

More information

Best Papers. F. Fusco

Best Papers. F. Fusco Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical

More information

Jaspreet S. Sandhu,*,, Geoffrey T. Gotto,*, Luis A. Herran, Peter T. Scardino, James A. Eastham and Farhang Rabbani

Jaspreet S. Sandhu,*,, Geoffrey T. Gotto,*, Luis A. Herran, Peter T. Scardino, James A. Eastham and Farhang Rabbani Age, Obesity, Medical Comorbidities and Surgical Technique are Predictive of Symptomatic Anastomotic Strictures After Contemporary Radical Prostatectomy Jaspreet S. Sandhu,*,, Geoffrey T. Gotto,*, Luis

More information

Elsevier Editorial System(tm) for European Urology Manuscript Draft

Elsevier Editorial System(tm) for European Urology Manuscript Draft Elsevier Editorial System(tm) for European Urology Manuscript Draft Manuscript Number: EURUROL-D-13-00306 Title: Post-Prostatectomy Incontinence and Pelvic Floor Muscle Training: A Defining Problem Article

More information

Interval from Prostate Biopsy to Robot-Assisted Laparoscopic Radical Prostatectomy (RALP): Effects on Surgical Difficulties

Interval from Prostate Biopsy to Robot-Assisted Laparoscopic Radical Prostatectomy (RALP): Effects on Surgical Difficulties www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.10.4 Urological Oncology Interval from Prostate Biopsy to RobotAssisted Laparoscopic Radical Prostatectomy (RALP): Effects on Surgical Difficulties

More information

Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series

Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,

More information

Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer

Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer Preliminary Results from the National Program of Cancer Registries Patterns of Care Study (PoC1) NAACCR Annual Meeting

More information

TOOKAD (padeliporfin) Patient Information Guide

TOOKAD (padeliporfin) Patient Information Guide TOOKAD (padeliporfin) Patient Information Guide TOOKAD is used to treat low-risk localized prostate cancer This medicine is subject to additional monitoring. This will allow quick identification of new

More information

MORE THAN 140,000 men in the United States annually

MORE THAN 140,000 men in the United States annually Time Course and Predictors of Symptoms After Primary Prostate Cancer Therapy By James A. Talcott, Judith Manola, Jack A. Clark, Irving Kaplan, Clair J. Beard, Sonya P. Mitchell, Ronald C. Chen, Michael

More information

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics

More information

Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer

Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer after prostatectomy, radiation therapy and HiFU R. Schwartzberg, E. Günther, N. Klein, S. Zapf, R. El-Idrissi, J. Cooper, B.

More information

Prostate Cancer. David Wilkinson MD Gulfshore Urology

Prostate Cancer. David Wilkinson MD Gulfshore Urology Prostate Cancer David Wilkinson MD Gulfshore Urology What is the Prostate? Male Sexual Gland Adds nutrients and fluids for sperm This fluid is added to sperm during ejaculation Urethra (urine channel)

More information

A quantitative analysis of the costs and benefits of prostate cancer screening

A quantitative analysis of the costs and benefits of prostate cancer screening (2001) 4, 138 145 ß 2001 Nature Publishing Group All rights reserved 1365 7852/01 $15.00 www.nature.com/pcan A quantitative analysis of the costs and benefits of prostate cancer screening RM Benoit 1 *

More information

Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer

Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung

More information

Radiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008

Radiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008 Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators

More information

journal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract

journal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,

More information

Accepted for publication 3 January 2005

Accepted for publication 3 January 2005 Original Article RACIAL DIFFERENCES IN PSA DOUBLING TIME AND RECURRENCE TEWARI et al. In a multi-institutional study authors from the USA and Austria attempt to determine if there are differences in several

More information

Prognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy

Prognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence

More information

NEOADJUVANT ENDOCRINE THERAPY PRIOR TO NERVE-SPARING

NEOADJUVANT ENDOCRINE THERAPY PRIOR TO NERVE-SPARING NEOADJUVANT ENDOCRINE THERAPY PRIOR TO NERVE-SPARING RADICAL PROSTATECTOMY IN PATIENTS WITH STAGE T2 PROSTATIC CANCER Takeshi Uedal, Hiroomi Nakatsul, Shigeo Isaka2 and Jun Shimazaki2 1Urology, Kumagaya

More information

Survival outcomes for men in rural and remote NSW. Trend in prostate cancer incidence and mortality rates in Australia. The prostate cancer conundrum

Survival outcomes for men in rural and remote NSW. Trend in prostate cancer incidence and mortality rates in Australia. The prostate cancer conundrum 7/8/20 7/8/20 Using PROMS to better understand prostate cancer outcomes: The NSW Prostate Cancer Care and Outcomes Study David Smith Research Fellow Cancer Research Division Monash Uni, 26 th June 20 Survival

More information

Comiter CV (2002). "The male sling for stress urinary incontinence: a prospective study." J Urol 167(2 Pt 1):

Comiter CV (2002). The male sling for stress urinary incontinence: a prospective study. J Urol 167(2 Pt 1): Bacon, C. G., E. Giovannucci, et al. (2002). "The association of treatment-related symptoms with qualityof-life outcomes for localized prostate carcinoma patients." Cancer 94(3): 862-71. BACKGROUND: Most

More information

5-YEAR URINARY AND SEXUAL OUTCOMES AFTER RADICAL PROSTATECTOMY: RESULTS FROM THE PROSTATE CANCER OUTCOMES STUDY

5-YEAR URINARY AND SEXUAL OUTCOMES AFTER RADICAL PROSTATECTOMY: RESULTS FROM THE PROSTATE CANCER OUTCOMES STUDY 0022-5347/05/1735-1701/0 Reprinted from Vol. 173, 1701 1705, May 2005 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2005 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000154637.38262.3a 5-YEAR

More information

Case Discussions: Prostate Cancer

Case Discussions: Prostate Cancer Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of

More information

Laparoscopic Surgery. The Da Vinci Robot. Limits of Laparoscopy. What Robotics Offers. Robotic Urologic Surgery: A New Era in Patient Care

Laparoscopic Surgery. The Da Vinci Robot. Limits of Laparoscopy. What Robotics Offers. Robotic Urologic Surgery: A New Era in Patient Care Laparoscopic Surgery Robotic Urologic Surgery: A New Era in Patient Care Laparoscopic technique was introduced in urologic surgery in the 1990s Benefits: Improved recovery time, decreased morbidity Matthew

More information

Open Prostatectomy is Best

Open Prostatectomy is Best Open Prostatectomy is Best William J. Catalona, M.D. The Trifecta Trifecta Cure Continence Potency Northwestern University Feinberg School of Medicine Eastham, J et al, JUrol 179:2207 Continence (Pad Free

More information

Introduction. The concept of race and prostate cancer. JW Moul 1 * Keywords: prostate; cancer; screening; black race; PSA

Introduction. The concept of race and prostate cancer. JW Moul 1 * Keywords: prostate; cancer; screening; black race; PSA (2000) 3, 248±255 ß 2000 Macmillan Publishers Ltd All rights reserved 1365±7852/00 $15.00 www.nature.com/pcan Targeted screening for prostate cancer in African-American men{ 1 * 1 Urology Service, Department

More information

Policy #: 370 Latest Review Date: April 2017

Policy #: 370 Latest Review Date: April 2017 Name of Policy: Nerve Graft with Radical Prostatectomy Policy #: 370 Latest Review Date: April 2017 Category: Surgery Policy Grade: B Background/Definitions: As a general rule, benefits are payable under

More information

Life after prostate cancer End your frustration. Restore your normalcy. Renew your confidence. Take the next step

Life after prostate cancer End your frustration. Restore your normalcy. Renew your confidence. Take the next step Take the next step Visit EDCure.org to: Take the online ED quiz and get your customized treatment results Find an ED specialist in your area Register for free educational seminars to learn more about treatment

More information

Suburethral sling at the time of radical prostatectomy in patients at high risk of postoperative incontinence

Suburethral sling at the time of radical prostatectomy in patients at high risk of postoperative incontinence Original Article IMMEDIATE SLING DURING RP IN HIGH-RISK PATIENTS WESTNEY et al. Suburethral sling at the time of radical prostatectomy in patients at high risk of postoperative incontinence O. LENAINE

More information

THE UROLOGY GROUP

THE UROLOGY GROUP THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,

More information

The UNIVERSITY of NEWCASTLE

The UNIVERSITY of NEWCASTLE The UNIVERSITY of NEWCASTLE R esearch C entre for G ender and H ealth Characteristics of Australian women with incontinence according to incontinence severity and treatment-seeking behaviour Results from

More information

Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC

Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,

More information

Information Content of Five Nomograms for Outcomes in Prostate Cancer

Information Content of Five Nomograms for Outcomes in Prostate Cancer Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:

More information

An Easy Prediction of Urinary Incontinence Duration After Retropubic Radical Prostatectomy Based on Urine Loss the First Day After Catheter Withdrawal

An Easy Prediction of Urinary Incontinence Duration After Retropubic Radical Prostatectomy Based on Urine Loss the First Day After Catheter Withdrawal An Easy Prediction of Urinary Incontinence Duration After Retropubic Radical Prostatectomy Based on Urine Loss the First Day After Catheter Withdrawal M. Van Kampen,* I. Geraerts, W. De Weerdt and H. Van

More information

Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy

Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy By: Jonathan Barlaan; Huy Nguyen Mentor: Julio Powsang, MD Reader: Richard Wilder, MD May 2, 211 Abstract Introduction: The

More information

concordance indices were calculated for the entire model and subsequently for each risk group.

concordance indices were calculated for the entire model and subsequently for each risk group. ; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai

More information

S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet

S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet Why HIFU? Efficacy demonstrated Real time control of the target Early control of the necrosis area is possible with MRI or TRUS using contrast

More information

Urodynamic Results of Sacral Neuromodulation Correlate with Subjective Improvement in Patients with an Overactive Bladder

Urodynamic Results of Sacral Neuromodulation Correlate with Subjective Improvement in Patients with an Overactive Bladder European Urology European Urology 43 (2003) 282±287 Urodynamic Results of Sacral Neuromodulation Correlate with Subjective Improvement in Patients with an Overactive Bladder W.A. Scheepens a, G.A. van

More information

Satisfaction and Regret after Open Retropubic or Robot- Assisted Laparoscopic Radical Prostatectomy

Satisfaction and Regret after Open Retropubic or Robot- Assisted Laparoscopic Radical Prostatectomy european urology 54 (2008) 785 793 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Satisfaction and Regret after Open Retropubic or Robot- Assisted Laparoscopic

More information

A Proposed Study of Hyperbaric Oxygen Therapy Following Radical Prostatectomy: Effects on Erectile Dysfunction

A Proposed Study of Hyperbaric Oxygen Therapy Following Radical Prostatectomy: Effects on Erectile Dysfunction A Proposed Study of Hyperbaric Oxygen Therapy Following Radical Prostatectomy: Effects on Erectile Dysfunction Anthony J. Bella MD, FRCSC Division of Urology, Department of Surgery and Department of Neuroscience

More information

Prostate Cancer: 2010 Guidelines Update

Prostate Cancer: 2010 Guidelines Update Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer

More information

A schematic of the rectal probe in contact with the prostate is show in this diagram.

A schematic of the rectal probe in contact with the prostate is show in this diagram. Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview

More information

Introduction. Original Article

Introduction. Original Article bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after

More information

High Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November D. Maruzzi - L. Ruggera

High Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November D. Maruzzi - L. Ruggera High Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November 2014 D. Maruzzi - L. Ruggera HIFU development Second prototype 1995-2000 Integrated Imaging 2006-2010 1993

More information

Prostate cancer. Treatments Side effects and management in the community setting

Prostate cancer. Treatments Side effects and management in the community setting Prostate cancer Treatments Side effects and management in the community setting Kristoffer Ohlin CNS Urology Janice Minter Lead Cancer Nurse St George s Hospital Agenda Prostate cancer treatments Radiotherapy

More information

Total Prostatectomy within 6 Weeks of a Prostate Biopsy: Is it Safe?

Total Prostatectomy within 6 Weeks of a Prostate Biopsy: Is it Safe? Clinical Urology Prostatectomy within 6 Weeks of Biopsy: Is it Safe? International Braz J Urol Vol. 36 (2): 177-182, March - April, 2010 doi: 10.1590/S1677-55382010000200007 Total Prostatectomy within

More information

Role of surgery. Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam

Role of surgery. Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Role of surgery Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Surgery and alternative treatments Radical prostatectomy Open Laparoscopic Robot-assisted Temperature

More information

Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series

Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series E. Z. Neulander 1, K. Rubinov 2, W. Mermershtain 2, Z. Wajsman 3 1 Department of Urology, Soroka

More information

estimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.

estimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c. . JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical

More information

A Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy

A Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy 168) Prague Medical Report / Vol. 112 (2011) No. 3, p. 168 176 A Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy

More information

Questions & Answers about Sexuality and Intimacy after Bladder Cancer. Part III: Causes and Treatments for Sexual Dysfunction

Questions & Answers about Sexuality and Intimacy after Bladder Cancer. Part III: Causes and Treatments for Sexual Dysfunction Questions & Answers about Sexuality and Intimacy after Bladder Cancer A Valentine's chat with Dr. Trinity Bivalacqua Monday, February 13, 2017 Part III: Causes and Treatments for Sexual Dysfunction Presented

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 146 Effective Health Care Program Therapies for Clinically Localized Prostate Cancer: Update of a 2008 Systematic Review Executive Summary Background Prostate cancer

More information

Early outcomes of active surveillance for localized prostate cancer

Early outcomes of active surveillance for localized prostate cancer Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,

More information

Management of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction

Management of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction Management of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction Robert C. Eyre, MD, FACS Associate Clinical Professor of Surgery (Urology) Harvard Medical School Post-prostatectomy Incontinence

More information

Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience

Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,

More information

SCIENTIFIC PAPER ABSTRACT INTRODUCTION METHODS

SCIENTIFIC PAPER ABSTRACT INTRODUCTION METHODS SCIENTIFIC PAPER Patient-Reported Validated Functional Outcome After Extraperitoneal Robotic-Assisted Nerve-Sparing Radical Prostatectomy Ralph Madeb, MD, Dragan Golijanin, MD, Joy Knopf, MD, Ivelisse

More information

Cancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:

Cancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject: Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained

More information

Clinical Study A Comparison of Radical Perineal, Radical Retropubic, and Robot-Assisted Laparoscopic Prostatectomies in a Single Surgeon Series

Clinical Study A Comparison of Radical Perineal, Radical Retropubic, and Robot-Assisted Laparoscopic Prostatectomies in a Single Surgeon Series Prostate Cancer Volume 2011, Article ID 878323, 6 pages doi:10.1155/2011/878323 Clinical Study A Comparison of Radical Perineal, Radical Retropubic, and Robot-Assisted Laparoscopic Prostatectomies in a

More information

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last

More information

Treatment Failure After Primary and Salvage Therapy for Prostate Cancer

Treatment Failure After Primary and Salvage Therapy for Prostate Cancer 307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2

More information

PSA Screening and Prostate Cancer. Rishi Modh, MD

PSA Screening and Prostate Cancer. Rishi Modh, MD PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University

More information

Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence

Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael

More information

Quality of Life After Modern Treatment Options for Prostate Cancer Ronald Chen, MD, MPH

Quality of Life After Modern Treatment Options for Prostate Cancer Ronald Chen, MD, MPH Quality of Life After Modern Treatment Options I will be presenting some recently published data on the quality of life after modern treatment options for prostate cancer. My name is Dr. Ronald Chen. I'm

More information

Prostatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London

Prostatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of

More information

BPH: a present and future perspective on health impact

BPH: a present and future perspective on health impact BPH: a present and future perspective on health impact Burden of disease in men with moderate LUTS Dalibor Pacík This presentation is financially supported by GlaxoSmithKline. CZ/DUTT/0019/12 Men with

More information

Effective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18

Effective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18 PROVIDENCE HEALTH PLANS MEDICAL (HIFU) (All Lines of Business Except Medicare) Effective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18 11/1/18 Medical Officer

More information

What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).

What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). It is a very common cancer in men; some cancers grow very slowly,

More information

Cytoreductive Radical Prostatectomy for de Novo Metastatic Prostate Cancer

Cytoreductive Radical Prostatectomy for de Novo Metastatic Prostate Cancer Cytoreductive Radical Prostatectomy for de Novo Metastatic Prostate Cancer Timothy G. Wilson, MD Professor and Chair of Urology John Wayne Cancer Institute Santa Monica, California Disclosures I am on

More information

External Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer

External Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer External Beam Therapy for Low/Intermediate Risk Prostate Cancer Jeff Michalski, M.D. The Carlos A. Perez Distinguished Professor of Department of and Siteman Cancer Center Learning Objectives Understand

More information

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA

More information

Prostate Cancer Incidence

Prostate Cancer Incidence Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases

More information

of Nebraska - Lincoln

of Nebraska - Lincoln University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Department of Veterans Affairs Staff Publications U.S. Department of Veterans Affairs 8-2000 Detection, Characterization,

More information

Prostate Cancer Innovations in Surgical Strategies Update 2007!

Prostate Cancer Innovations in Surgical Strategies Update 2007! Prostate Cancer Innovations in Surgical Strategies Update 2007! Curtis A. Pettaway, M.D. Professor Department of Urology The University of Texas M. D. Anderson Cancer Center Radical Prostatectomy Pathologic

More information

Objectives. Prostate Cancer Screening and Surgical Management

Objectives. Prostate Cancer Screening and Surgical Management Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Objectives Update

More information

Incontinence Patient Information Form

Incontinence Patient Information Form Incontinence Patient Information Form (To be completed by patient) Before talking with you, the doctor would like some information about your urine leakage. These questions are important for finding out

More information

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options INTRODUCTION This booklet describes how prostate cancer develops, how it affects the body and the current treatment methods. Although

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #102 (NQF 0389): Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS

More information

PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS

PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine

More information